Mabwell (Shanghai) Bioscience Co. Ltd. A
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of p… Read more
Mabwell (Shanghai) Bioscience Co. Ltd. A (688062) - Total Assets
Latest total assets as of September 2025: CN¥4.53 Billion CNY
Based on the latest financial reports, Mabwell (Shanghai) Bioscience Co. Ltd. A (688062) holds total assets worth CN¥4.53 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Mabwell (Shanghai) Bioscience Co. Ltd. A - Total Assets Trend (2017–2024)
This chart illustrates how Mabwell (Shanghai) Bioscience Co. Ltd. A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Mabwell (Shanghai) Bioscience Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Mabwell (Shanghai) Bioscience Co. Ltd. A's total assets of CN¥4.53 Billion consist of 39.9% current assets and 60.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 27.9% |
| Accounts Receivable | CN¥138.39 Million | 3.2% |
| Inventory | CN¥211.68 Million | 5.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥152.81 Million | 3.6% |
| Goodwill | CN¥118.77 Million | 2.8% |
Asset Composition Trend (2017–2024)
This chart illustrates how Mabwell (Shanghai) Bioscience Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mabwell (Shanghai) Bioscience Co. Ltd. A's current assets represent 39.9% of total assets in 2024, an increase from 36.6% in 2017.
- Cash Position: Cash and equivalents constituted 27.9% of total assets in 2024, up from 7.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 49.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 5.0% of total assets.
Mabwell (Shanghai) Bioscience Co. Ltd. A Competitors by Total Assets
Key competitors of Mabwell (Shanghai) Bioscience Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Mabwell (Shanghai) Bioscience Co. Ltd. A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Mabwell (Shanghai) Bioscience Co. Ltd. A generates 0.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Mabwell (Shanghai) Bioscience Co. Ltd. A is currently not profitable relative to its asset base.
Mabwell (Shanghai) Bioscience Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.90 | 1.40 | 6.71 |
| Quick Ratio | 0.81 | 1.25 | 6.49 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-212.99 Million | CN¥ 574.04 Million | CN¥ 860.99 Million |
Mabwell (Shanghai) Bioscience Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Mabwell (Shanghai) Bioscience Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 19.12 |
| Latest Market Cap to Assets Ratio | 0.22 |
| Asset Growth Rate (YoY) | -4.0% |
| Total Assets | CN¥4.28 Billion |
| Market Capitalization | $949.30 Million USD |
Valuation Analysis
Below Book Valuation: The market values Mabwell (Shanghai) Bioscience Co. Ltd. A's assets below their book value (0.22 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Mabwell (Shanghai) Bioscience Co. Ltd. A's assets decreased by 4.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Mabwell (Shanghai) Bioscience Co. Ltd. A (2017–2024)
The table below shows the annual total assets of Mabwell (Shanghai) Bioscience Co. Ltd. A from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.28 Billion | -4.03% |
| 2023-12-31 | CN¥4.46 Billion | -3.56% |
| 2022-12-31 | CN¥4.62 Billion | +189.57% |
| 2021-12-31 | CN¥1.60 Billion | -2.66% |
| 2020-12-31 | CN¥1.64 Billion | +52.84% |
| 2019-12-31 | CN¥1.07 Billion | +20.22% |
| 2018-12-31 | CN¥891.92 Million | +40.16% |
| 2017-12-31 | CN¥636.34 Million | -- |